November 17, 2016 / 11:47 AM / a year ago

BRIEF-Prometic's PBI-4050 demonstrates early evidence of efficacy in its IPF Phase 2 clinical trial

Nov 17 (Reuters) - Prometic Life Sciences Inc -

* Early evidence of efficacy of PBI-4050 alone and also in combination with one of commercially available IPF drugs

* PBI-4050 shown to be very well tolerated whether used alone or in combination with nintedanib or pirfenidone

* 4050 demonstrates early evidence of efficacy in its idiopathic pulmonary fibrosis (“IPF”) phase 2 clinical trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below